DATA FOR STUDIES ON AVASTIN.

DATA FOR STUDIES OF AVASTIN. The Avery Johnson article says that the UnitedHealth Group data shows that Avastin is used heavily for treating two types of cancer for which it has not been approved. It is prescribed for 24% of patients with non-small-cell lung cancer and for 41% of colon-cancer patients. The article says that the company characterizes these uses as “inappropriate”, and the focus of the article and the program seems to be on whether treatments conform to various professional protocols. My thought is that this is a wonderful opportunity to find out about the effectiveness of Avastin in different circumstances and provide guidance for future gold-standard clinical trials.